Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Scinopharm Taiwan's shares outstanding for the quarter that ended in Dec. 2025 was 791 Mil.
Scinopharm Taiwan's quarterly shares outstanding
stayed the same
from Sep. 2025 (791 Mil) to Dec. 2025 (791 Mil).
Scinopharm Taiwan's annual shares outstanding
stayed the same
from Dec. 2024 (791 Mil) to Dec. 2025 (791 Mil).
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Scinopharm Taiwan Shares Outstanding (EOP) Related Terms
Scinopharm Taiwan Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1789 vs ZTS, UTHR: Shares Outstanding (EOP) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Shares Outstanding (EOP) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 791 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Shares Outstanding (EOP) of 791 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Shares Outstanding (EOP) too high?
Scinopharm Taiwan's current Shares Outstanding (EOP) is 791 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Shares Outstanding (EOP) compare to ZTS and UTHR?
Scinopharm Taiwan's Shares Outstanding (EOP) of 791 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Shares Outstanding (EOP) is 791 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.15, compared to a current price of NT$20.85 — trading 23.2% below its estimated fair value. The current Shares Outstanding (EOP) is 791 Mil. Scinopharm Taiwan's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Shares Outstanding (EOP) is 791 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.85 is trading 23.2% below its estimated GF Value™ of NT$27.15.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Shares Outstanding (EOP): 791 Mil
GF Value™: NT$27.15 vs. price of NT$20.85 (23.2% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
75GF Score
Get the complete analysis for TPE:1789
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
